[Elevated creatine kinase activity in serum following oral application of a beta2-mimetic broncholytic drug (NAB 365) (author's transl)].
In 25 patients with chronic bronchitis it was shown by a study of 9 months' duration (3 months before treatment, 6 months under treatment) that after peroral application of 4-amino-alpha-[(tert.-butylamino)methyl]-3,5-dichlorobenzyl alcohol hydrochloride (clenbuterol, NAB 365) elevations of the activity of creatine kinase occur without other recognizable signs and symptoms. The isoenzyme of creatine kinase were differentiated by immunological means and proved to be of the MM-type in additional 9 patients. The significance of the elevations of creatine kinase activity in serum even after peroral intake of drugs has been discussed.
D000328:Adult; D000368:Aged; D001993:Bronchodilator Agents / Q000494:pharmacology*; D002082:Butylamines / Q000494:pharmacology*; D003402:Creatine Kinase / Q000097:blood*; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000201:enzymology
D001993:Bronchodilator Agents; D002082:Butylamines; D007527:Isoenzymes; D003402:Creatine Kinase
Anstieg der Creatinkinase-Aktivität im Serum bei peroraler Gabe eines beta2-mimetischen Broncholytikums (NAB 365)